MLNT - Melinta Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
Enterprise Value 3
Trailing P/E
Forward P/E 1
PEG Ratio (5 yr expected) 1
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue 3
Enterprise Value/EBITDA 6

Trading Information

Stock Price History

Beta (3Y Monthly) 7.14
52-Week Change 3-87.13%
S&P500 52-Week Change 315.97%
52 Week High 314.2500
52 Week Low 31.0300
50-Day Moving Average 33.2949
200-Day Moving Average 33.4794

Share Statistics

Avg Vol (3 month) 3514.13k
Avg Vol (10 day) 3961.98k
Shares Outstanding 513.75M
Float 10.29M
% Held by Insiders 17.28%
% Held by Institutions 162.46%
Shares Short (Oct 31, 2019) 42.07M
Short Ratio (Oct 31, 2019) 43.9
Short % of Float (Oct 31, 2019) 424.47%
Short % of Shares Outstanding (Oct 31, 2019) 415.03%
Shares Short (prior month Sep 30, 2019) 41.63M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 25/1
Last Split Date 3Feb 22, 2019

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Sep 30, 2019


Profit Margin 0.00%
Operating Margin (ttm)-107.11%

Management Effectiveness

Return on Assets (ttm)-15.33%
Return on Equity (ttm)-367.54%

Income Statement

Revenue (ttm)81.4M
Revenue Per Share (ttm)6.78
Quarterly Revenue Growth (yoy)-53.40%
Gross Profit (ttm)952k
EBITDA -70.49M
Net Income Avi to Common (ttm)-320.21M
Diluted EPS (ttm)-26.6860
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)63.52M
Total Cash Per Share (mrq)4.62
Total Debt (mrq)157.98M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)1.02
Book Value Per Share (mrq)-4.40

Cash Flow Statement

Operating Cash Flow (ttm)-90.65M
Levered Free Cash Flow (ttm)-45.02M